SINGAPORE (Jan 12): Maybank Kim Eng is maintaining its “buy” call on Raffles Medical Group with an unchanged target price of $1.85 as the research house remains positive on the stock’s long-term growth, particularly in the case of its overseas projects.

“Raffles Medical is positive on China’s private healthcare industry and the value that its ‘Raffles model’ can bring. This emphasises teamwork, transparent pricing, thorough case auditing and high-quality treatment.

Management studied the Chinese market for more than three decades before venturing there,” shares analyst John Cheong in a report published last Monday.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
Related Stories

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook